On #WorldMalariaDay, we reflect on the progress achieved and reaffirm our commitment to a malaria-free future. Sustained investment in prevention, control, and eradication efforts is crucial. We are at a pivotal moment 🌍 Help support our lifesaving efforts give.path.org/campaign/665...

Combining #malaria interventions like chemoprevention, bed nets and vaccines can be highly effective, and as researchers argue in a report published in the Malaria Journal, implementation context is paramount. Read more: bit.ly/4cpc3AP

Accelerating progress for maternal & newborn health could save over 7 million lives by the end of this decade. 📢 This #WorldHealthDay, learn how advocates & decision-makers can drive action to help moms and children survive + thrive: bit.ly/4couuWm #HopefulFutures @who.int

This #WorldHealthDay, we highlight our GiveWell Perennial Malaria Chemoprevention project that has helped more than 43,000 children in the DRC start their #healthybeginning by delivering antimalarial drugs to infants and children in their first 2 years of life.

The fight against malaria needs the energy and innovation of young leaders. With the right support and resources, the youth can drive action and mobilize funding to end malaria for good. It's our future, let's protect it. #PowerUpHealth @pathmalaria.bsky.social @malariaconsortium.bsky.social

Everyone has a right to lifesaving vaccines, no matter where they live. At PATH, we’re proud to work with @gavi.org to give hundreds of millions of children a fair chance at a healthy life. But millions more still miss out. It’s time to fully fund Gavi ➡️ bit.ly/3KQTvMQ #VaccinesWork #ForOurFuture

No child should miss out on protection from a vaccine-preventable disease. Learn more about Burkina Faso’s efforts to end typhoid: www.path.org/our-impact/a... #GlobalHealth #VaccinesWork

🎉It's #WorldNTDDay! 1.5 billion people remain affected by Neglected Tropical Diseases. We are proud to join the collective movement to #UniteActEliminate and #EndNTDs!

🌟 The first point-of-care diagnostic test for G6PD deficiency has achieved @who.int prequalification 🌟 Developed by SD Biosensor & PATH, the STANDARD G6PD Test is a critically needed tool. Congrats to the many partners who contributed to this milestone in the fight to #EndMalaria! bit.ly/3PKB0fj

As we face multiple health crises — including #mpox, #cholera, and #AMR — a strong & effective @who.int is more critical than ever. We urge the Trump Administration to reconsider its position on US withdrawal from WHO. Read our full statement: bit.ly/3EhfXys

#VaccinesWork ✨ @gavi.org reports on Cameroon’s #malaria vaccine rollout, one year into the campaign ⏬

@pathmalaria.bsky.social is hiring! Are you an early-career professional interested in building your skills in data analysis through a mentorship program while providing support to National Malaria Programs in either DRC, CAR, or Nigeria? Check us out! path.wd1.myworkdayjobs.com/en-US/Extern...

As another year ends, @PATHMalaria reflects on all we've accomplished with our partners. We remain committed to the audacious goal to #EndMalaria for all, even amidst challenges like #AMDR and climate change. In this 🧵, we share photos illustrating key moments in 2024. (1/11)

@who.int has released their #WorldMalariaReport! Although major progress has been made, we must continue to commit ourselves to an equitable and aligned fight against #malaria. bit.ly/3VzeTvE

New study from Namibia shows that malaria rapid diagnostic tests (RDTs) can stay positive for weeks after treatment. Standard RDTs had a median positivity of 42 days, while new ultra-sensitive RDTs remined positive for 67 days. Implications for surveillance & elimination. 🦟🔬 tinyurl.com/ymfrbwjz

Exciting news: @who.int has prequalified tafenoquine, a single-dose treatment for relapsing P. vivax malaria, and added it to their latest #malaria guidelines. Check it out 👇https://www.mmv.org/newsroom/news-resources-search/first-single-dose-medicine-p-vivax-malaria-prequalified-who-and

Fresh from ASTMH, PATH malaria team are excited to get started on Bluesky! Who's good to follow? Anyone read any good papers recently?